Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T

Open source

DOI: 10.1136/bmjopen-2025-102626
Published: 2025 Aug 27
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-102626,
  title = {Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.},
  author = {Matikas A and Naume B and Wildiers H and Sonke G and Dieci MV and Karakatsanis A and Andersson A and Barnekow E and Kessler LE and Einbeigi Z and Killander F and Linderholm B and Schiza A and Valachis A and Nearchou A and Engebraaten O and Porojnicu A and Soland MH and Mannsåker B and Raj SX and Blix ES and Nordstrand CS and Lambertini M and Vernieri C and Punie K and Sotiriou C and Bergh J and Villacampa G and Zouzos A and Hellström M and Hartman J and Foukakis T},
  year = {2025},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-102626},
  url = {https://doi.org/10.1136/bmjopen-2025-102626}
}

RIS

TY  - JOUR
TI  - Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
AU  - Matikas A
AU  - Naume B
AU  - Wildiers H
AU  - Sonke G
AU  - Dieci MV
AU  - Karakatsanis A
AU  - Andersson A
AU  - Barnekow E
AU  - Kessler LE
AU  - Einbeigi Z
AU  - Killander F
AU  - Linderholm B
AU  - Schiza A
AU  - Valachis A
AU  - Nearchou A
AU  - Engebraaten O
AU  - Porojnicu A
AU  - Soland MH
AU  - Mannsåker B
AU  - Raj SX
AU  - Blix ES
AU  - Nordstrand CS
AU  - Lambertini M
AU  - Vernieri C
AU  - Punie K
AU  - Sotiriou C
AU  - Bergh J
AU  - Villacampa G
AU  - Zouzos A
AU  - Hellström M
AU  - Hartman J
AU  - Foukakis T
PY  - 2025
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-102626
UR  - https://doi.org/10.1136/bmjopen-2025-102626
ER  -

APA

A, M., B, N., H, W., G, S., MV, D., A, K., A, A., E, B., LE, K., Z, E., F, K., B, L., A, S., A, V., A, N., O, E., A, P., MH, S., B, M., SX, R., ES, B., CS, N., M, L., C, V., K, P., C, S., J, B., G, V., A, Z., M, H., J, H., & T, F. (2025). Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.. BMJ open. https://doi.org/10.1136/bmjopen-2025-102626

Source records

pubmed · retrieved 2026-09-27T00:37:29.621Z